Glutamine vinyl ester proteasome inhibitors selective for trypsin-like (beta2) subunit

Area of Science:

• Medicinal Chemistry
• Biochemistry
• Drug Discovery

Background:

• The proteasome is a crucial protein complex involved in cellular protein degradation.
• Proteasome inhibitors are a significant class of drugs, particularly in cancer therapy.
• Developing novel inhibitors with improved selectivity and stability remains an active area of research.

Purpose of the Study:

• To synthesize and evaluate a new series of peptide-based proteasome inhibitors.
• To investigate the structure-activity relationships of these inhibitors, focusing on C-terminal modifications and central amino acid substitutions.
• To identify potent and selective inhibitors targeting specific proteasome subunits.

Main Methods:

• Synthesis of peptide derivatives incorporating a vinyl ester moiety.
• In vitro enzymatic assays to assess proteasome inhibition.
• Structure-activity relationship (SAR) analysis to determine the impact of specific amino acids (e.g., Tic) and functional groups on activity.
• Evaluation of enzymatic stability.

Main Results:

• A series of peptide-based proteasome inhibitors with a vinyl ester C-terminus were synthesized and characterized.
• The incorporation of Tic, a phenylalanine analogue, in the central part of the peptides was found to reduce inhibitory activity.
• The lead compound exhibited potent and selective inhibition of the proteasome beta2 subunit.
• The best analogue demonstrated favorable enzymatic stability.

Conclusions:

• Novel peptide-based proteasome inhibitors featuring a vinyl ester moiety have been developed.
• Structural modifications, specifically the inclusion of Tic, can negatively impact inhibitory potency.
• The most effective inhibitor displays high selectivity for the beta2 subunit and good enzymatic stability, suggesting therapeutic potential.